Glaukos Corporation Common Stock (NY:GKOS)

133.60 -2.25 (-1.66%)

Streaming Delayed Price Updated: 12:56 PM EDT, May 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

RadiusXR and Glaukos Corporation Announce a New Collaboration With Topcon Healthcare, Inc. and the Launch of Inspire®: A Next-Generation Visual Field Solution

March 11, 2025

From Glaukos Corporation

Via Business Wire

Here's How Much $100 Invested In Glaukos 5 Years Ago Would Be Worth Today ↗

February 24, 2025

Via Benzinga

FDA Sets Decision Date For Glaukos' Keratoconus Treatment Without The Need Of Surgery ↗

February 24, 2025

Glaukos' Epioxa NDA for keratoconus is under FDA review, with a decision expected by October 2025. Phase 3 trials support its non-invasive treatment potential.

Via Benzinga

Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™

February 24, 2025

From Glaukos Corporation

Via Business Wire

Earnings Scheduled For February 20, 2025 ↗

February 20, 2025

Via Benzinga

Peering Into Glaukos's Recent Short Interest ↗

February 12, 2025

Via Benzinga

How Is The Market Feeling About Glaukos? ↗

January 27, 2025

Via Benzinga

Consumer Sentiment Drops 10%, UnitedHealth Under Investigation: What's Driving Markets Friday? ↗

February 21, 2025

All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.

Via Benzinga

Glaukos Delivers Mixed Q4 Results, Analyst Sees Growing Investor Interest During Transition ↗

February 21, 2025

Glaukos reported Q4 sales of $105.5 million, surpassing estimates, while EPS missed. Analysts see strong growth potential as the company expands its business model.

Via Benzinga

Wondering what's happening in today's after-hours session? ↗

February 20, 2025

As the regular session of the US market on Thursday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

$1000 Invested In Glaukos 5 Years Ago Would Be Worth This Much Today ↗

January 23, 2025

Via Benzinga

What 11 Analyst Ratings Have To Say About Glaukos ↗

December 31, 2024

Via Benzinga

(GKOS) - Analyzing Glaukos's Short Interest ↗

December 26, 2024

Via Benzinga

How Is The Market Feeling About Glaukos? ↗

December 03, 2024

Via Benzinga

Glaukos Announces Fourth Quarter and Full Year 2024 Financial Results

February 20, 2025

From Glaukos Corporation

Via Business Wire

This NetApp Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

February 19, 2025

Via Benzinga

Glaukos to Release Fourth Quarter and Full Year 2024 Financial Results after Market Close on February 20

January 23, 2025

From Glaukos Corporation

Via Business Wire

Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform

January 14, 2025

From Glaukos Corporation

Via Business Wire

Analyst Scoreboard: 5 Ratings For Glaukos ↗

November 26, 2024

Via Benzinga

Short Seller Accuses TransMedics Of 'Mafia Style' Scheme, Organ Transplant Company Says Short Seller Manipulating Market ↗

January 13, 2025

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.

Via Benzinga

Topics Fraud

Glaukos To Rally Around 17%? Here Are 6 Top Analyst Forecasts For Tuesday ↗

December 31, 2024

Via Benzinga

Glaukos Submits New Drug Application to U.S. FDA for Epioxa™

December 23, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Announces Participation in the J.P. Morgan Healthcare Conference

December 17, 2024

From Glaukos Corporation

Via Business Wire

Wall Street's Top 10 Stock Calls This Week - Saturday, Dec. 7 ↗

December 07, 2024

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Dec. 2-6, 2024.

Via Talk Markets

Topics Stocks / Equities

This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday ↗

December 06, 2024

Via Benzinga

Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos ↗

December 02, 2024

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.

Via Benzinga

This Kohl's Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday ↗

December 02, 2024

Via Benzinga

Glaukos Announces Participation in Upcoming Investor Conferences

November 08, 2024

From Glaukos Corporation

Via Business Wire

Glaukos Reports 30% Boost In Glaucoma Sales, Improved Margins In Q3, Analyst Highlights Certain Headwinds ↗

November 05, 2024

Glaukos Corporation's Q3 revenue grew 24% to $96.7 million, beating estimates, with an EPS loss of $(0.28). 2024 sales guidance raised despite anticipated headwinds.

Via Benzinga

Glaukos Announces Third Quarter 2024 Financial Results

November 04, 2024

From Glaukos Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.